Top Ten Biopharma Selects Kneat as its Corporate Validation Platform for Global Manufacturing
In
The customer's goal is to roll Kneat out in phases for multiple processes across all its manufacturing sites. The initial focus is Facilities, Utilities, and Equipment Qualification across several lead sites. Follow on processes include, Cleaning Validation, Process Validation, Manufacturing Changeover, Engineering Specifications, Technology Transfer, Regulatory Information Management, and more GMP verification processes.
As a COVID-19 vaccine manufacturer, Kneat's roll-out will also facilitate efficiencies and speed in the validation documentation practices that support COVID-19 production. Kneat is privileged to be assisting with this urgent and essential global need.
'With the addition of this global leader we are pleased to now be the chosen corporate solution for seven of the top ten largest pharmaceutical companies,' said
Phase 1 implementation will begin in the coming weeks, with the initial go-live expected in Q4 2021.
Financing Update
In connection with the closing of the common share offering announced on
About Kneat
Kneat, a Canadian company with operational headquarters in Limerick,
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes 'forward-looking information' within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and the customer, Kneat's business development activities, the use and implementation timelines of Kneat's software within the customer's validation processes, the ability and intent of the customer to scale the use of Kneat's software within the customer's organization and the compliance of Kneat's platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors' own risk.
Contact:
Tel: +353 61 203826
Email: investors@kneat.com
(C) 2021 Electronic News Publishing, source